Back to mobile site

Emergent BioSolutions (EBS) Tops Q1 EPS by 142c, provides guidanvce

May 1, 2024 5:07 PM EDT

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.59, $1.42 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $300.4 million versus the consensus estimate of $185.4 million.

GUIDANCE:

Emergent BioSolutions sees FY2024 revenue of $1-1.1 billion, versus the consensus of $1.015 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings